Covid Vaccine Race

A third dose of the Pfizer-BioNTech or AstraZeneca mRNA COVID-19 vaccines produced sufficient neutralizing antibody titers against the Omicron variant.

Former members of the Biden transition team recommend accepting that the virus is here to stay.

As global health leaders discuss the best long-term strategy for COVID-19 vaccines and boosters, consensus is emerging that repeated boosters of current vaccines within short intervals is not sustainable.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

Pfizer CEO Albert Bourla made the announcement in an interview.

New data suggests an additional “booster” dose of an mRNA COVID-19 vaccine is no longer just recommended but required for protection against the infectious Omicron variant.

Vaccine hesitancy is a significant hurdle experienced in the US. In response to this, a team of researchers analyzed adults who reported a medical provider recommended the COVID-19 vaccine, studied vaccination status, and general attitudes.

After increased awareness soon after the emergence of COVID-19, fewer Americans see plight of people of color.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.

Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

Side effects that occur during concurrent vaccine administrations can influence future vaccine decisions.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.